720374Novel age appropriate formulation of glycopyrroniumClosedGRD Development of PrototypeInnovate UKProveca plans to develop a novel oral formulation of glycopyrronium for the treatment of sialorrhea or Chronic Pathological Drooling (CPD) in children. CPD is a common and disabling manifestation of several neurological disorders including cerebral palsy and amyotrophic lateral sclerosis and for which no treatment is currently licensed. It is an often overlooked condition with consequences that are both medical and psychological. These include irritated and macerated facial skin, dehydration, constant wetness and foul odour of clothing, interference with interpersonal relationships and lowering of self-esteem. Following a successful TSB Proof of Market grant to develop the business case for a novel glycopyrronium formulation to treat severe CPD, this follow on grant funding will enable Proveca to develop a prototype formulation for clinical trial testing and paediatric licensing (via the Paediatric Use Marketing Authorisation route).